Pays: Afrique du Sud
Langue: anglais
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
PHENERINE TABLETS SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): PHENERINE TABLETS COMPOSITION: Each tablet contains 50 mg orphenadrine hydrochloride PHARMACOLOGICAL CLASSIFICATION: A 5.4.1 Anti-Parkinsonism preparations. PHARMACOLOGICAL ACTION : Orphenadrine hydrochloride is a centrally acting anticholinergic agent of benefit in Parkinsonism. It favourably influences akinesia, rigidity and tremor as well as secondary symptoms such as depressed mood, sialorrhea and hyperhidrosis. INDICATIONS: Parkinsonism. CONTRA-INDICATIONS: Prostatic enlargement, paralytic ileus, pyloric stenosis, closed-angle glaucoma and patients with a narrow angle between the iris and the cornea. Should be used with caution in conditions characterised by tachycardia such as thyrotoxicosis, cardiac insufficiency or failure, and in cardiac surgery. WARNING: KEEP OUT OF REACH OF CHILDREN. DOSAGE AND DIRECTIONS FOR USE: One tablet twice a day to two tablets four times a day. SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Dryness of the mouth with difficulty in swallowing, thirst, dilatation of the pupils with loss of accommodation and photophobia, increased intra-ocular pressure, flushing and dryness of the skin, bradycardia followed by tachycardia, with palpitations and arrhythmias, a desire to urinate with the inability to do so, as well as reduction in the tone and motility of the gastro-intestinal tract leading to constipation. Occasionally vomiting, giddiness and staggering may occur. Retrosternal pain may occur due to increased gastric reflux. In the treatment of Parkinsonism, increases in dosage, and transfer to other forms of treatment should be gradual and anticholinergic agents should not be withdrawn abruptly. If higher doses provoke severe mental disturbances the drug should be discontinued, but minor reactions ma Lire le document complet